Background -The average age of patients with lung cancer is increasing and there are large numbers of elderly symptomatic patients with this common disease. However, there are few data on how the treatment of this group differs from that of younger patients. Methods -From 1 January 1990 information was collected for the Southend Lung Cancer Registry on all patients with a diagnosis of lung cancer in a geographically well defined health district of the UK with a population of 325 000. Every effort was made to find new cases from all departments of the hospital, including all clinical diagnoses, histopathological and cytological reports, and necropsies. All death certificates in the district were examined, irrespective of age, for any diagnosis of lung cancer. This therefore included any patient not seen by the hospital services. The differences in initial treatment have been analysed for three age groups: under 65, 65-74 years, and over 75. Results -The 563 cases of lung cancer diagnosed during a 30 month period were included in the study, of whom 240 (43%) were aged over 75 years. The overall mean age was 71 years (range 31-95). The incidence oflung cancer in the general population was 69 per 100 000, but in men over 75 years of age it rose to 751 per 100 000. For all patients the active treatment rate (chemotherapy, surgery, or radiotherapy) was 49%, but for patients not reviewed by a chest physician (n = 86) it was only 21%. There were large differences in initial treatment between age groups. For patients with non-small cell lung cancer (NSCLC) reviewed by a chest physician, surgery was undertaken in 18% of those under 65, 12% of the 65-74 age group, and 2*1% of those over 75. For patients with small cell lung cancer (SCLC) reviewed by a chest physician, 79% ofthose aged under 65, 64% of the 65-74 age group, and 41% of patients aged over 75 received chemotherapy. In patients with NSCLC reviewed by a chest physician, chemotherapy was given to 21% under 65, 6-4% in the [65][66][67][68][69][70][71][72][73][74] age group, and none over 75. If no histological diagnosis was made 37% ofpatients aged under 75 and only 5-4% of those over 75 received either surgery, radiotherapy, or chemotherapy. Patients not reviewed by a chest physician were less likely to have had a histological diagnosis. Differences in treatment rates with age persisted even after allowing for performance score status at presentation. Conclusions -Lung cancer is a common disease in the elderly and, in our district, 43% of patients were aged 75 or over at presentation. Age alone appeared to be a major factor in influencing treatment choices, and treatment was more likely if histological confirmation was obtained. Further detailed analysis of the reasons for the differences is needed. Patients referred to chest physicians were more likely to have both histological confirmation and active treatment. This study supports the contention that all patients with a diagnosis of lung cancer, irrespective of age or condition, should be assessed by an accredited chest physician. (Thorax 1996;51:564-568) 
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2For difference in active initial treatment between age groups for all patients reviewed by chest physician, p<0001, X2 55.
'For difference in active initial treatment between age groups for all patients with no histology, p<0-001, X2= 21. 'For difference in active initial treatment between age groups for all patients with NSCLC, p<0001 %2 = 22. ' For SCLC patients, age group differences for chemotherapy, p = 0-0026, x2= 9.1 (X2 test for trend).
2 For NSCLC, age group differences for symptomatic treatment only, p<0-001, X2 = 22 (X2 test for trend). average age for patients not reviewed by a chest physician supports this view and at least partially explains the high proportion of elderly patients with lung cancer. The rate of histological confirmation in our study is high at 74% and compares favourably with other series. 5 14 We elected to study initial treatment only, to identify patients given an active treatment policy. Follow up treatment would generally be radiotherapy for palliation of symptoms not considered to warrant treatment at the time of diagnosis. Despite the fact that over a quarter of patients aged over 75 years were allocated to one of the "active" treatments, we have clearly shown a large effect of age on treatment decisions with older patients being less likely to receive "active" treatment. The differences are most marked for patients with NSCLC where surgery or chemotherapy were only undertaken in two patients aged over 75 years. There was also a strong trend for decreasing use of chemotherapy for SCLC with increasing age, offset by an increase in the number of patients given radiotherapy.
The possible reasons for different treatment of elderly patients from younger patients are numerous. We have shown that, if no histological diagnosis was made, "active" treatment was less frequently given with only 5-4% of such patients over 75 receiving it. Although we recognise it may be inappropriate to perform invasive procedures in frail patients with a poor prognosis, failure to make a histological diagnosis in the elderly may be one cause of less active treatment. Our study shows that the older patients, as expected, are generally less fit and this is associated with lower treatment rates. However, when divided into groups according to the ECOG scale, there was still a large difference in treatment rates by age for patients in the higher performance categories (table 6). Although this study was confined to one health district, we believe the results are probably representative of other districts within the UK as our overall initial treatment rate of 56% for patients reviewed by a chest physician is similar to other studies which included follow up treatment. 8 Advanced age has been proposed as a risk factor for inadequate treatment 
